Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.
about
Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid.Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution.Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans.
P2860
Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.
@en
type
label
Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.
@en
prefLabel
Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.
@en
P2093
P2860
P356
P1476
Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.
@en
P2093
Apurva Patel
David Tenero
Etienne Dumont
Gary Bowers
John Tomayko
Keith A Rodvold
Milena Kurtinecz
Parul Patel
P2860
P304
P356
10.1128/AAC.02483-12
P407
P577
2013-05-06T00:00:00Z